-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Azenosertib in Uterine Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Azenosertib in Uterine CancerDrug Details:Azenosertib (ZNC-3) is under development for the treatment solid tumors including relapsed...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Azenosertib in Ovarian Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Azenosertib in Ovarian CancerDrug Details:Azenosertib (ZNC-3) is under development for the treatment solid tumors including relapsed...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Azenosertib in Fallopian Tube Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Azenosertib in Fallopian Tube CancerDrug Details:Azenosertib (ZNC-3) is under development for the treatment solid tumors including...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Azenosertib in Solid Tumor
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Azenosertib in Solid TumorDrug Details:Azenosertib (ZNC-3) is under development for the treatment solid tumors including relapsed...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Azenosertib in Osteosarcoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Azenosertib in OsteosarcomaDrug Details:Azenosertib (ZNC-3) is under development for the treatment solid tumors including relapsed or...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Trastuzumab duocarmazine in Ovarian Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Trastuzumab duocarmazine in Ovarian Cancer Drug Details: Trastuzumab duocarmazine (SYD-985) is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Azenosertib in Solid Tumor
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Azenosertib in Solid Tumor Drug Details: Azenosertib (ZNC-3) is under development for the treatment solid...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Azenosertib in Fallopian Tube Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Azenosertib in Fallopian Tube Cancer Drug Details: Azenosertib (ZNC-3) is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Azenosertib in Peritoneal Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Azenosertib in Peritoneal Cancer Drug Details: Azenosertib (ZNC-3) is under development for the treatment solid...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Trastuzumab duocarmazine in Endometrial Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Trastuzumab duocarmazine in Endometrial Cancer Drug Details: Trastuzumab duocarmazine (SYD-985) is under development for the...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.